Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Probiotics reduce infectious complications after pancreaticoduodenectomy.
Nomura T, Tsuchiya Y, Nashimoto A, Yabusaki H, Takii Y, Nakagawa S, Sato N, Kanbayashi C, Tanaka O. Nomura T, et al. Among authors: kanbayashi c. Hepatogastroenterology. 2007 Apr-May;54(75):661-3. Hepatogastroenterology. 2007. PMID: 17591036 Clinical Trial.
[Trastuzumab-associated cardiac dysfunction].
Okada Y, Kanbayashi C, Sato N. Okada Y, et al. Among authors: kanbayashi c. Gan To Kagaku Ryoho. 2010 Apr;37(4):665-9. Gan To Kagaku Ryoho. 2010. PMID: 20414023 Japanese.
Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study.
Shigekawa T, Osaki A, Sekine H, Sato N, Kanbayashi C, Sano H, Takeuchi H, Ueda S, Nakamiya N, Sugitani I, Sugiyama M, Shimada H, Hirokawa E, Takahashi T, Saeki T. Shigekawa T, et al. Among authors: kanbayashi c. BMC Cancer. 2015 Apr 10;15:253. doi: 10.1186/s12885-015-1289-7. BMC Cancer. 2015. PMID: 25884795 Free PMC article.
Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study.
Shien T, Doihara H, Sato N, Anan K, Komaki K, Miyauchi K, Yanagita Y, Fujisawa T, Mitsuyama S, Kanbayashi C, Kusama M, Kimura M, Jinno H, Sano M, Ikeda T. Shien T, et al. Among authors: kanbayashi c. Cancer Chemother Pharmacol. 2018 Feb;81(2):269-275. doi: 10.1007/s00280-017-3491-6. Epub 2017 Dec 1. Cancer Chemother Pharmacol. 2018. PMID: 29196963 Free PMC article. Clinical Trial.
Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.
Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. Sato N, et al. Among authors: kanbayashi c. Cancer Med. 2018 Jul;7(7):3044-3056. doi: 10.1002/cam4.1600. Epub 2018 Jun 14. Cancer Med. 2018. PMID: 29905023 Free PMC article.
Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.
Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. Sato N, et al. Among authors: kanbayashi c. Cancer Med. 2019 Sep;8(12):5468-5481. doi: 10.1002/cam4.2423. Epub 2019 Jul 30. Cancer Med. 2019. PMID: 31361400 Free PMC article. Clinical Trial.
42 results